171 related articles for article (PubMed ID: 35523073)
21. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy.
Shepard HM
Front Oncol; 2015; 5():192. PubMed ID: 26380222
[TBL] [Abstract][Full Text] [Related]
22. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
[TBL] [Abstract][Full Text] [Related]
23. Computational modeling of therapy on pancreatic cancer in its early stages.
Chen J; Weihs D; Vermolen FJ
Biomech Model Mechanobiol; 2020 Apr; 19(2):427-444. PubMed ID: 31501963
[TBL] [Abstract][Full Text] [Related]
24. Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer.
Fan YF; Shang WT; Lu GH; Guo KX; Deng H; Zhu XH; Wang CC; Tian J
Cancer Lett; 2021 Dec; 523():1-9. PubMed ID: 34530049
[TBL] [Abstract][Full Text] [Related]
25. Effective targeting of the tumor microenvironment for cancer therapy.
Jiang P; Li X; Thompson CB; Huang Z; Araiza F; Osgood R; Wei G; Feldmann M; Frost GI; Shepard HM
Anticancer Res; 2012 Apr; 32(4):1203-12. PubMed ID: 22493350
[TBL] [Abstract][Full Text] [Related]
26. Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy.
Clift R; Souratha J; Garrovillo SA; Zimmerman S; Blouw B
Cancer Res; 2019 Aug; 79(16):4149-4159. PubMed ID: 31248966
[TBL] [Abstract][Full Text] [Related]
27. Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20).
Arias-Lorza AM; Costello JR; Hingorani SR; Von Hoff DD; Korn RL; Raghunand N
Res Sq; 2023 Sep; ():. PubMed ID: 37720027
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dodecafluoropentane Nano-Emulsion-Preliminary Findings.
Johnson JL; Leos RA; Baker AF; Unger EC
J Biomed Nanotechnol; 2015 Feb; 11(2):274-81. PubMed ID: 26349303
[TBL] [Abstract][Full Text] [Related]
29. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S
Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686
[TBL] [Abstract][Full Text] [Related]
30. Synthetic extracellular matrix enhances tumor growth and metastasis in an orthotopic mouse model of pancreatic adenocarcinoma.
Scaife CL; Shea JE; Dai Q; Firpo MA; Prestwich GD; Mulvihill SJ
J Gastrointest Surg; 2008 Jun; 12(6):1074-80. PubMed ID: 18057994
[TBL] [Abstract][Full Text] [Related]
31. In Vivo Imaging Reveals Significant Tumor Vascular Dysfunction and Increased Tumor Hypoxia-Inducible Factor-1α Expression Induced by High Single-Dose Irradiation in a Pancreatic Tumor Model.
Maeda A; Chen Y; Bu J; Mujcic H; Wouters BG; DaCosta RS
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):184-194. PubMed ID: 27816364
[TBL] [Abstract][Full Text] [Related]
32. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.
Whatcott CJ; Han H; Posner RG; Hostetter G; Von Hoff DD
Cancer Discov; 2011 Sep; 1(4):291-6. PubMed ID: 22053288
[TBL] [Abstract][Full Text] [Related]
33. High-Molecular-Weight Hyaluronan Is a Hippo Pathway Ligand Directing Cell Density-Dependent Growth Inhibition via PAR1b.
Ooki T; Murata-Kamiya N; Takahashi-Kanemitsu A; Wu W; Hatakeyama M
Dev Cell; 2019 May; 49(4):590-604.e9. PubMed ID: 31080060
[TBL] [Abstract][Full Text] [Related]
34. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis.
Bharadwaj AG; Rector K; Simpson MA
J Biol Chem; 2007 Jul; 282(28):20561-72. PubMed ID: 17502371
[TBL] [Abstract][Full Text] [Related]
35. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma.
Kudo D; Suto A; Hakamada K
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282922
[TBL] [Abstract][Full Text] [Related]
36. Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma.
Maloney E; DuFort CC; Provenzano PP; Farr N; Carlson MA; Vohra R; Park J; Hingorani SR; Lee D
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167451
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Schwartz DL; Bankson JA; Lemos R; Lai SY; Thittai AK; He Y; Hostetter G; Demeure MJ; Von Hoff DD; Powis G
Mol Cancer Ther; 2010 Jul; 9(7):2057-67. PubMed ID: 20587661
[TBL] [Abstract][Full Text] [Related]
38. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
39. The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Erkan M; Kurtoglu M; Kleeff J
Expert Rev Gastroenterol Hepatol; 2016; 10(3):301-16. PubMed ID: 26560854
[TBL] [Abstract][Full Text] [Related]
40. Hyaluronidase reduces human breast cancer xenografts in SCID mice.
Shuster S; Frost GI; Csoka AB; Formby B; Stern R
Int J Cancer; 2002 Nov; 102(2):192-7. PubMed ID: 12385018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
